GT Medical Technologies Completes $100 Million Series E to Advance GammaTile in Operable Brain Tumors on June 10, 2026 Brain Neoplasms Evidity Health Capital GammaTile Gilde GT Medical Technologies Health care facility MVM Operable Brain Tumors oversubscribed Partner in relationship Series E Viking Global Investors +